Tesamorelin research, identity and evidence limits
Tesamorelin is a GHRH analogue approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. It is not indicated for general weight-loss management.
Identity and formulation
Tesamorelin stimulates the growth-hormone pathway through a releasing-hormone mechanism. It is distinct from growth hormone itself, sermorelin and other modified GHRH products.
Current Egrifta WR and Egrifta SV formulations are not substitutable. Their product-specific preparation and exposure requirements should not be mixed.
What the studies show
Controlled studies show reductions in visceral abdominal fat in selected adults with HIV. Another small trial investigated liver fat in that population. These findings should not be restated as a general obesity treatment, a guaranteed reduction in body weight or approval for every form of fatty-liver disease.
| Study and design | Finding | What it does not establish |
|---|---|---|
| Metabolic effects of a growth hormone-releasing factor in patients with HIV.
Twenty-six-week randomized placebo-controlled trial in 412 adults with HIV and abdominal fat accumulation Reading scope: PubMed bibliographic record and abstract |
Visceral adipose tissue fell with tesamorelin while it rose slightly with placebo; IGF-1 increased and more participants stopped treatment because of adverse events. | The population and abdominal-fat endpoint differ from general obesity treatment and long-term cardiovascular outcomes. |
| Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.
Six-month randomized double-blind trial in 50 adults with HIV Reading scope: PubMed bibliographic record and abstract |
Visceral and liver fat decreased. Fasting glucose rose early, although the later difference was not statistically significant. | This small study does not establish a general fatty-liver indication, and an early glucose signal should not be omitted because of the later result. |
For the differences between a mechanism, a biomarker and a clinical outcome, see the evidence-reading guide.
How to interpret the findings
Visceral fat measured by imaging is different from total weight on a scale. A product can affect one without delivering a comparable change in the other.
The label explicitly excludes general weight-loss management and says long-term cardiovascular safety has not been established. A favorable body-composition result is not proof of fewer heart attacks or improved survival.
IGF-1 and glucose changes matter to the treatment context. A growth-pathway marker should not be marketed solely as evidence that the intervention is working.
Safety context
The current Egrifta WR label includes contraindications involving active malignancy and disruption of the hypothalamic-pituitary axis, along with IGF-1 and glucose-related monitoring.
A research summary cannot determine an individual’s suitability. The evidence comes from selected participants receiving clinical follow-up, not from unrestricted use for abdominal appearance.
Study exposure and units
Keep the original trial formulation and treatment duration attached to the result. A current formulation’s nominal amount should not be copied from an older study or a different Egrifta version.
Distinguish a change during active treatment from a persistent effect after stopping. Long-term maintenance and clinical outcomes require follow-up beyond an initial imaging result.
Match any reported amount or concentration to the exact material, route, population and duration in the original experiment. Read the guide to mass, volume and concentration for the meaning of common units. A calculation cannot establish an appropriate treatment or validate an untested formulation.
Product identity and report checks
Identify the exact tesamorelin product and formulation. A GHRH-family assay or a sermorelin report is not an identity match.
If a listing invokes Egrifta evidence, determine whether it actually supplies that pharmaceutical product. A raw-powder assay does not establish formulation equivalence or substantiate the same finished-product claims.
Keep the clinical evidence and the supplier evidence separate. Use the report-verification steps to check the issuer and the batch questions to connect a tested sample with the product offered. Compare prices using the delivered-cost method rather than an isolated discount or purity percentage.
Peptide Serum operates a store as well as this research library. The supplier directory contains imported seller information; a listing is not laboratory certification. Read how this library is prepared and evaluate the documentation for the exact lot offered. A seller rating does not establish clinical safety or effectiveness.
Common questions
Does tesamorelin primarily establish general weight loss?
No. Its labeled purpose concerns excess abdominal fat in adults with HIV-associated lipodystrophy. The key trials emphasize visceral fat.
Does the liver-fat trial mean it is approved for all fatty-liver disease?
No. The trial is a specific study in adults with HIV; a broader indication would need its own evidence and regulatory basis.
Can Egrifta WR and SV instructions be swapped?
No. The current label specifically states that the formulations are not substitutable.
Sources
- Metabolic effects of a growth hormone-releasing factor in patients with HIV. (PubMed bibliographic record and abstract)
- Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. (PubMed bibliographic record and abstract)
- Egrifta WR prescribing label (Official primary page, relevant sections)